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Abstract
Background: It is uncertain whether patients with renal vascular disease will have renal or
mortality benefit from re-establishing renal blood flow with renal revascularization procedures. The
RAVE study will compare renal revascularization to medical management for people with
atherosclerotic renal vascular disease (ARVD) and the indication for revascularization. Patients will
be assessed for the standard nephrology research outcomes of progression to doubling of
creatinine, need for dialysis, and death, as well as other cardiovascular outcomes. We will also
establish whether the use of a new inexpensive, simple and available ultrasound test, the renal
resistance index (RRI), can identify patients with renal vascular disease who will not benefit from
renal revascularization procedures[1].
Methods/design:  This single center randomized, parallel group, pilot study comparing renal
revascularization with medical therapy alone will help establish an infrastructure and test the
feasibility of answering this important question in clinical nephrology. The main outcome will be a
composite of death, dialysis and doubling of creatinine. Knowledge from this study will be used to
better understand the natural history of patients diagnosed with renal vascular disease in
anticipation of a Canadian multicenter trial. Data collected from this study will also inform the
Canadian Hypertension Education Program (CHEP) Clinical Practice Guidelines for the
management of Renal and Renal Vascular Disease. The expectation is that this program for ARVD,
will enable community based programs to implement a comprehensive guidelines based diagnostic
and treatment program, help create an evidence based approach for the management of patients
with this condition, and possibly reduce or halt the progression of kidney disease in these patients.
Discussion: Results from this study will determine the feasibility of a multicentered study for the
management of renovascular disease.
Background
End-stage renal disease (ESRD) comprises an enormous
public health burden, with an incidence and prevalence
that are increasing alarmingly[2]. The two most common
causes of ESRD are diabetic nephropathy and hyperten-
sion while ARVD is the most rapidly increasing cause. The
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prevalence of ARVD is 2% of those with essential hyper-
tension rising in those with severe hypertension or resist-
ant hypertension to 20–40%[3,4]. There is no preferred,
evidence based pathway for the diagnosis and manage-
ment of ARVD, and the clinical practice guidelines
describing the investigation and treatment of this condi-
tion are complex and based to a great extent on opin-
ion[5,6]. Some of the diagnostic tests are very expensive.
The therapeutic procedure for treating the condition,
revascularization, is invasive, expensive, particularly if a
stent is used, and it is not yet clear whether revasculariza-
tion helps to preserve or restore kidney function.
Atherosclerotic renovascular disease
ARVD occurs from progressive atherosclerosis of the arter-
ies of the kidneys as a result of the effects of factors such
as high blood pressure, diabetes, elevated cholesterol and
smoking on the blood vessel walls. Narrowing of the large
and/or small arteries of the kidneys leads to renal
ischemia. Affected areas of the kidney, responding to pro-
gressively lower blood flow rates, try to restore their blood
flow by producing renin leading to elevated levels of angi-
otensin II and aldosterone. These hormones cause sys-
temic hypertension, aggravating the atherosclerotic
process and completing a positive feedback loop[7].
Higher blood pressure further damages the arteries of the
kidneys causing renal ischemia, fibrosis and progressive
loss of renal mass and renal function, which is also a stim-
ulus for higher blood pressure. ARVD typically occurs in
an older population group, with risk factors for and evi-
dence of, generalized atherosclerosis. Fibromuscular dys-
plasia, a cause of renal artery stenosis that presents at a
much younger age, is not the subject of this study and
patients with this condition will be excluded through the
inclusion and exclusion criteria.
A recent meta analysis demonstrated that revasculariza-
tion of the renal artery in patients with > 50% narrowing,
resulted in only a small improvement in blood pressure
control when compared to medical management[8]. In
addition, no benefit in renal outcomes were found. The
studies in the meta-analysis focused on treating anatomi-
cal lesions rather than focusing on the recognition and
prevention of intrarenal parenchyma damage. This dam-
age to the nephrons, the filtering units of the kidney, has
been found to be more important in the pathogenesis of
renal dysfunction than the presence of renal artery sten-
oses > 50% of the vessel lumens[9]. Renal protection strat-
egies which include blood pressure control, the use of
aspirin and cholesterol reduction with statins are part of
the medical management to prevent renal parenchyma
disease[10]. Revascularizing lesions of the renal artery
greater than 50%, may help to improve blood flow to
affected areas of the kidney. However, if the affected areas
have already suffered renal parenchyma damage, then
restoring blood flow will not result in an improvement in
renal function. Thus a diagnostic strategy that could effec-
tively identify patients who will not benefit from revascu-
larization could save patients from invasive and costly
tests which will not benefit them.
Diagnosis of ARVD
Early diagnosis and treatment of ARVD may help to
improve hypertension and prevent renal impairment. The
current diagnostic recommendations from the Canadian
Hypertension Education Program clinical practice guide-
lines can be found in Table 1. Clinically, signs of renal
artery stenosis include; abdominal bruit, resistant hyper-
tension requiring three or more anti-hypertensive medica-
tions, accelerated or suddenly uncontrolled hypertension
and atherosclerosis in other vascular beds. Stenoses less
than 50% are not associated with renal impairment or
hypertension[11], but those greater than 50% can cause
both[7]. Early onset of hypertension before the age of 30
suggests fibromuscular dysplasia, an as yet idiopathic
form of renal artery disease and not the subject of this
study. Sudden onset of resistant hypertension after the age
of 55 years suggests ARVD as does differences in the size
of both kidneys greater than 1 cm, on ultrasound. These
clinical signs can help identify a patient with increased
likelihood of disease. Once ARVD is suspected, a screen-
ing test should be performed to confirm its presence. One
of the greatest challenges in managing ARVD is that there
is no single screening test with sufficient sensitivity and
specificity to confidently identify patients who will bene-
fit from revascularization. For example while renal angi-
ography can identify whether there is macrovascular renal
artery disease which is amenable to percutaneous translu-
minal renal angioplasty (PTRA) with or without a stent, it
can not determine if the lesion is responsible for the clin-
ical picture or predict whether revascularization will
improve blood pressure control or preserve renal func-
tion. Angiographic procedures may cause renal harm by
introducing contrast dye directly into the kidney as well as
introducing athero-emboli by disrupting atheroma along
the vessel wall[12]. While revascularization studies have
demonstrated good anatomical correction of renal vascu-
lar lesions, particularly with renal stenting (which costs
many thousands of dollars)[13], even meta analyses of
studies of clinical revascularization have shown no
improvement in renal function compared to conservative
strategies and modest if any improvement in blood pres-
sure control[8]. In general, studies of PTRA without or
with stenting (PTRAS) for ARVD have shown that renal
function is improved in about 25%, stabilizes in about
40%, but worsens in about 25% of patients[14].
Diagnostic screening tests
The ideal single screening test for ARVD would be accu-
rate, have low technical failure, high sensitivity and specif-BMC Nephrology 2007, 8:4 http://www.biomedcentral.com/1471-2369/8/4
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icity and it should be non-invasive and inexpensive[1,15].
Magnetic resonance imaging (MRI) and spiral CT are non-
invasive and have high sensitivity and specificity but have
high costs and for spiral CT include the risk for contrast
dye. MRI is also contraindicated for patients with claustro-
phobia, metallic implants or for the seriously ill. Simple
measurements of serum renin have been investigated to
predict the potential success of surgical revascularization
but the frequency of false-negative and false-positive
results make this screening test unhelpful[16]. Even when
the accuracy of the serum renin test is enhanced by the
addition of an ACEi (angiotensin converting enzyme
inhibitor) the test still has insufficient specificity and sen-
sitivity to be recommended[17]. Also, renin based diag-
nostic tests are limited by antihypertensive drugs that
interfere with plasma renin activity.
The captopril renal scan can detect ARVD with high sensi-
tivity and reasonable specificity and also gives informa-
tion on the potential for blood pressure lowering
following revascularization[11]. This test is limited in that
it cannot locate the stenosis or determine its severity and
it has not been shown to predict improvements in renal
function[18]. Also the sensitivity of this test is reduced in
patients with renal insufficiency or bilateral stenoses or a
single kidney with vascular stenosis, clinical scenarios
common enough to exclude this test alone as a screening
tool[19].
Doppler ultrasonography has been demonstrated to have
high sensitivity and specificity in experienced hands for
the diagnosis of anatomical lesions[20]. It can also detect
unilateral and bilateral lesions, accessory renal artery ste-
nosis, is non-invasive and is not expensive. Obesity, exces-
sive bowel gas or poor blood flow in the main renal artery
can interfere with direct visualization. The RRI performed
as part of a Doppler ultrasound exam is a powerful tool
for identifying patients that may not benefit from revascu-
larization. It is easy to learn and can effectively be applied
to all patients referred for a simple abdominal ultrasound
as part of the initial investigation for ARVD.
Preservation of renal function and blood pressure control
are the benefits that make the risks of renal revasculariza-
tion acceptable. Presently none of the diagnostic tests for
ARVD alone are sufficient to a) determine the presence of
an anatomical lesion suitable for revascularization and b)
determine whether revascularization will lead to blood
pressure control and renal preservation. This has led to
great heterogeneity in the diagnostic investigation of
ARVD and a focus on the more easily recognized and
treatable anatomical disease. With no single screening
test, standard of care for diagnosis of ARVD involves mul-
tiple screening tests including a renal ultrasound for renal
size with Doppler analysis of the renal arteries and a cap-
topril renal scan to determine the presence of renal artery
disease and its functional significance. To confirm the
diagnosis in those with intermediate or high probability
of renal vascular disease, an MR angiogram rather than
renal angiography is used to avoid nephrotoxic contrast
and the need for the insertion of a wire into the renal
artery with risk of atheroemboli. This test has high sensi-
tivity and specificity is non-invasive and uses gadolinium
for the contrast agent making it safe for patients with
chronic kidney disease. In a meta-analysis, Vasbinder
found that gadolinium-enhanced MRA and CT angiogra-
phy had the best diagnostic accuracy even in patients with
ARVD with renal insufficiency[21]. Because contrast dye is
contra-indicated in many patients with ARVD due to
chronic kidney disease this test is preferred over renal ang-
iography or spiral CT.
Renal resistance index
The RRI is a recently described test which may be able to
select patients with pre-existing renal parenchyma disease
that may not benefit from revascularization. This diagnos-
tic test has not yet been tested in a randomized prospec-
tive study but has tremendous potential to help patients
avoid unneeded tests. It is therefore a key component of
the RAVE study.
The RRI was described by Radermacher in 2001[1]. It
describes the amount of renal arterial impedance and is
calculated as ((peak systolic velocity - end diastolic veloc-
ity)/peak systolic velocity) × 100 averaged over 4–6 meas-
ures in the upper, middle and lower kidney[1]. In
univariate analysis it was found to have an odds ratio for
detecting those who would have worsening of renal func-
tion after renal revascularization of over 100, orders of
magnitude greater than the other known predictive fac-
Table 1: Clinical clues to suggest the presence of atherosclerotic renovascular disease
Clinical clues
• DBP >95 or ISH with uncontrolled BP despite 2 drugs.
• Declining GFR – Creatinine rises >20% with ACEI/ARB or >20% rise over 1 year without glomerulonephritis or diabetes.
• Hypokalemia with hypertension, high renin.
• Abdominal bruit.
• Flash pulmonary edema.
• Peripheral vascular disease and other atherosclerotic manifestations -coronary artery disease, cerebrovascular disease.
• Atherosclerotic risk factors – older age (> 55), smoking, hyperlipidemia, diabetes, hypertension, male gender.BMC Nephrology 2007, 8:4 http://www.biomedcentral.com/1471-2369/8/4
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tors[1]. Presently it is not in wide use but has great poten-
tial to exclude patients who will not benefit from
revascularization. Radermacher has shown that in
patients with renal artery stenosis an increase in the RRI ≥
80% is associated with poor renal outcomes and modest
if any effects on blood pressure control following revascu-
larization consistent with micro vascular disease leading
to renal parenchymal disease[1]. For example, in one
study following revascularization, in subjects with RRI ≥
80% none had blood pressure lowering, 46% required
dialysis and 29% died while in those with RRI < 80%, fol-
lowing revascularization there was significantly lower
blood pressure, 3% went on to dialysis and 3% died[1]. In
both univariate and multivariate analyses, the RRI was
shown to be the only reliable predictor of progression of
renal disease in patients with renal artery stenosis and
identified those whose blood pressure and renal function
was unlikely to improve with intervention[1,22,23].
Renal revascularization
Indications for renal revascularization include blood pres-
sure which remains above target despite medical therapy
and/or deterioration in renal function despite medical
therapy. Surgery was considered the standard revasculari-
zation procedure in the past but is now a backup for PTRA
because of the lower morbidity and mortality with the less
invasive procedure[16]. Not every patient with ARVD will
benefit from intervention and improvement may be seen
in blood pressure in only 60% of unselected
patients[16,24]. This falls to 25–30% in those with renal
insufficiency [25]. Studies comparing revascularization to
conservative therapy have never used the RRI and have
reported only slight to no benefit for blood pressure con-
trol and no preservation of renal function [8, 26]. Hyper-
tensive nephrosclerosis and diabetes as well as other
clinical factors (those found in Table 2) are not sensitive
or specific enough to predict those patients who are most
likely to benefit from renal revascularization, or those
who should not have revascularization[16].
In summary, the evidence to guide selection of the patient
who is most likely to benefit from renal revascularization
is limited. Identifying patients most likely to benefit from
revascularization is of prime importance to limit the risk
of diagnostic angiography and revascularization in those
who are unlikely to derive a benefit. The RRI potentially
could identify patients in whom revascularization should
not be considered and those in whom revascularization is
more likely to be successful.
Methods/Design
Study aims
The primary objective of the RAVE study is to determine
the frequency of progression to the composite endpoint,
death, dialysis and doubling of creatinine, in patients with
ARVD and an indication for revascularization, rand-
omized to medical therapy or renal revascularization over
a minimum of 6 months. The secondary objectives are to
compare blood pressure and medications used in patients
randomized to revascularization or medical therapy,
determine the sensitivity and specificity of the RRI in iden-
tifying the response to renal revascularization, to deter-
mine baseline factors in people with ARVD that are
associated with the indication for revascularization and to
follow patients over time for both an intent-to-treat and
per protocol analysis of outcomes stratified by their renal
resistance index finding.
Study design and setting
RAVE is a randomized controlled trial with blinding of
patients, health care providers and all study staff and out-
come assessors. In the study, patients with newly diag-
nosed renal artery stenosis from MR or CT angiography
that have an indication for renal revascularization are ran-
domized to receive either renal revascularization by PTRA
with stenting or medical therapy alone.
Ethical considerations
Ethical approval has been obtained at Sunnybrook Health
Sciences Centre.
Study interventions
The intervention is assignment to a group receiving medi-
cal therapy alone. The standard of care currently for
patients with renal artery stenosis and an indication for
revascularization is to have revascularization. Medical
therapy includes aggressive blood pressure lowering to
target (< 140/90 mm Hg and < 130/80 mm Hg for those
with diabetes), LDL reduction < 2.0 with statin therapy,
use of ASA or other antiplatelet therapy, diabetes control,
diet, exercise and smoking cessation. Referral for diabetes
education and management if appropriate.
Table 2: Factors associated with lower likelihood of response to 
renal revascularization[1]
Factors
• Urinary protein excretion ≥1 g/d,
• GFR < 40 ml/min
• pulse pressure of at least 70 mmHg
• male gender
• duration of hypertension > 10 years
• no history of smoking
• cerebrovascular disease
• hyperuricemia
• age > 65
• DBP < 80 mmHg, SBP < 160 mmHg
• no abrupt onset in blood pressure
• Diabetes mellitus
• coronary artery disease
• peripheral arterial diseaseBMC Nephrology 2007, 8:4 http://www.biomedcentral.com/1471-2369/8/4
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Percuateneous transluminal renal angioplasty, involves
percutaneous access to the arterial circulation using the
Seldinger technique at the level of the femoral artery and
the passing of an angiographic wire into the renal artery
and proximal aorta for contrast dye injection. Patients are
admitted to the nephrology ward the day of the procedure
and are discharged the following day after lab work has
been completed and reviewed. Antihypertensives are
given at half dose on the day of the procedure to prevent
symptomatic hypotension. ASA is held the day of the pro-
cedure. For those on coumadin, it is held 5 days before
and vitamin K 1 mg administered and a normal INR is
required prior to the procedure. Stenting will be per-
formed at the discretion of the angiographer. Angioplasty
of the renal artery with stenting leads to lower restenosis
rates and longer term patency [27]. While it seems logical
that this greater patency would lead to improved blood
pressure control and preservation of renal function, no
study has yet been conducted to prove this.
The choice of balloon size, angiographic method and
need for stent will be determined on a case by case basis
by the angiographer. In general stents are used for those
patients with ostial lesions. Renal revascularization to
date has not demonstrated in most patients in blood pres-
sure control and has shown no benefit in renal preserva-
tion. The DRASTIC study, the largest study to investigate
the effectiveness of a revascularization strategy for ARVD
had to screen over 1200 patients referred with resistant
hypertension to find 543 who received angiography for
diastolic blood pressure ≥ 95 mm Hg. Of these, 169
(30%) were found to have renal artery lesions ≥ 50% [28].
The DRASTIC study did not use renal stenting and did not
preselect patients using the RRI. Patients that require sur-
gical revascularization will be withdrawn from the study.
Identification of eligible patients
Patients referred to a renal vascular clinic in an academic
health sciences center will be eligible to enter the study.
This clinic is devoted to the diagnosis and management of
renal vascular disease. After referral, patients have a mini-
mum data set of screening laboratory and diagnostic tests
and screening diagnostic tests including a renal ultra-
sound, Doppler of the renal arteries and RRI. At the base-
line visit after collecting appropriate history physical
examination and lab data to document the risk factors
signs and symptoms of ARVD all the tests are reviewed. If
the patient has an intermediate or high probability for
revascularization based on a clinical assessment of the his-
tory, physical, lab and screening tests, an MR angiogram
or CT angiogram is arranged. All patients receive aggres-
sive medical management aimed at cardiovascular and
renal risk reduction with a focus on blood pressure and
lipid control and use of (Acetyl-salicylic acid) ASA. In this
protocol, patients assessed at the baseline visit who are
diagnosed with ARVD will be asked to consent to this
study. Randomization to revascularization or medical
management will take place later for those patients that
develop indications for revascularization. All patients
with renal vascular disease are followed at three month
intervals. Following revascularization, patients are seen
monthly for six months. Patients enrolled in the study will
be receiving appropriate medical care according to clinical
practice guidelines and will be considered part of regular
clinical practice. No additional tests or procedures other
than the consent to participate in a study, will be per-
formed on those participating in this study.
Randomization and study blinding
Following informed consent patients found to have renal
artery stenosis will be randomized in a permuted block
design with blocks of 2 and 4. The randomization sched-
ule has been developed and will be administered by the
Biomedical Design and Statistics unit. The randomization
code will be kept in a sealed opaque envelope and will not
be opened until the patient has an indication for revascu-
larization or the study end is reached. The study investiga-
tors, coordinators and patients and all members of the
research team will be aware of the randomization when
opened but will be blinded to the results of the renal
resistance index. The allocation will be administered by
study nurse in sealed sequentially numbered envelopes.
The study nurse will open the next number in sequence
when a randomization has occurred. The date and time of
randomization will be recorded and the opened randomi-
zation envelope will be filed in the trial centre binder.
Primary outcome
The primary objective of the RAVE study is to determine
the frequency of progression to the composite endpoint,
death or dialysis or doubling of creatinine, in patients
with ARVD stratified by the renal resistance index.
Patients with an indication for revascularization will be
openly randomized to medical therapy alone or to renal
revascularization as well as medical therapy.
Following revascularization patients will be assessed
monthly for 6 months and then every three months. All
patients will have at least 6 months of follow-up. The
blood pressure and creatinine level at the final visit will be
used for the analysis. If an outcome is reached during the
study, patients will continue to be followed, but data for
the main outcome measure will be based on only the first
endpoint reached. Outcomes will be analyzed on an
intent-to-treat basis.
Secondary outcome
The secondary objectives are to; 1. Compare blood pres-
sure and medications used in patients randomized to
revascularization or medical therapy, 2. determine theBMC Nephrology 2007, 8:4 http://www.biomedcentral.com/1471-2369/8/4
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sensitivity and specificity of the RRI in identifying the
response to renal revascularization, 3. determine baseline
factors in people with ARVD that are associated with the
indication for revascularization and 4. to follow patients
over time for both an intent-to-treat and per protocol
analysis of outcomes stratified by their renal resistance
index finding.
Data collection
Data will be collected into an Microsoft Access data base
designed to capture initial visit information and generate
a consultation note. Baseline data and ongoing data col-
lection as outlined in Table 4 will be obtained.
Patient follow-up procedures
Any patient randomized to medical therapy who has an
indication for revascularization will have attempted fur-
ther medical management for another 3 months. Patients
randomized to revascularization who have an indication
will be offered revascularization. All patients will be fol-
lowed prospectively for both an intent to treat and per
protocol analysis. The analysis will also be carried out
stratified by the result of the renal resistance index (nor-
mal vs abnormal) to determine it's prognostic ability.
The decision to proceed toward revascularization will be
based on a rise in creatinine by > 20% per year from base-
line for year one and in year 2, by > 20% over the average
creatinine from year one. To reduce the possibility that the
rise in creatinine is temporary, due for example to a hypo-
volemic event, a repeat creatinine will be required from 3
days to 3 months later to confirm that the creatinine has
risen by 20%. If an ACEi or ARB has been started after
enrollment into the study, a rise in creatinine of 20% in
the first 3 months after the initiation will be permitted.
The creatinine trigger for revascularization after ACEi or
ARB is started will be a creatinine rise of 40% during that
year. The blood pressure trigger for revascularization will
be systolic blood pressure ≥ 150 mmHg and/or diastolic
blood pressure ≥ 95 mmHg on any visit.
Patients randomized to the medical management group
will not be excluded from revascularization. If blood pres-
sure is ≥ 170 mm Hg and/or diastolic blood pressure ≥
100 mm Hg on any visit despite treatment with at least
three antihypertensives at maximal dosage patients can be
referred for revascularization. In this circumstance,
patients will continue to be assessed in an intent-to-treat
analysis. If the creatinine doubles from baseline patients
can be referred for revascularization.
Study withdrawal
Patients will be censored and withdrawn from follow-up
at their request. Patients will be censored at the time they
reach an endpoint including the need for renal replace-
ment therapy, death or doubling of the creatinine from
baseline.
Statistical analysis
This is a pilot study. The expected number of patients
enrolled and time-frame of the study will allow an appro-
priate sample size calculation for a large multicentered
study. The goal is to recruit 20 patients with renal vascular
disease. Over the study period, 20% of these are expected
to have indications for revascularization. Radermacher
found that 20% of patients with ARVD had RRI ≥ 80 but
it is likely that a greater fraction of those who require
revascularization will have a high RRI[16]. It is estimated
Table 3: Study inclusion and exclusion criteria
Inclusion criteria:
• age 55 and older.
• systolic blood pressure > 140 mmHg and/or diastolic > 90 mmHg despite at least 3 antihypertensive medications.
• systolic blood pressure > 140 mmHg and/or diastolic > 90 mmHg on two antihypertensives with; a rise in creatinine > 20% after initiation of an 
ACEi or ARB
• the sudden onset of hypertension occurring after age 55
• hypokalemia
• the presence of an abdominal bruit
• history of flash pulmonary edema,
• three of; Peripheral vascular disease, coronary artery disease, cerebrovascular disease, smoking, hyperlipidemia, diabetes or male gender.
Exclusion Criteria:
• serum creatinine > 220 umol/L or estimated GFR by Cockroft Gault equation < 20 ml/min.
• patients who are unwilling or unable to give informed consent.
• Known contraindication to renal revascularization such as anaphylactic allergy to contrast dye
• an abdominal aortic aneurysm requiring surgery
• a single functioning kidney
• a total occlusion of the renal artery
• renal artery stenosis due to fibromuscular dysplasia
• previous revascularization.BMC Nephrology 2007, 8:4 http://www.biomedcentral.com/1471-2369/8/4
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that this will be 1/3 in this study. This should lead to
enough patients in each group to gather meaningful infor-
mation to plan a larger study.
Sample size considerations
At the time the study was planned, it was expected that the
renal vascular clinic would take in an expected 240
patients over 1.5 years. During this time at least 20% of
the patients are expected to have an indication for revas-
cularization. The minimum follow-up for those getting
revascularized will be 6 months and the maximum possi-
ble 24 months. Based on the previous studies by Rader-
macher, 20% of subjects with ARVD will have RRI ≥
80[24]. It is unknown what fraction of those who have an
indication for revascularization will have an RRI ≥ 80 but
it is likely greater than 20%. An estimate of 1/3 of the
revascularization group will be used. The numbers are
likely to distribute as seen in Table 5. The purpose of the
pilot is in part to determine this distribution of patients so
that a large randomized study can be planned.
In the DRASTIC study, with follow up for one year, 8% of
those randomized had elevations of creatinine by at least
50% [28]. The patients in the RAVE study are likely to
have a greater rate of progression to end points as they will
be a more severe group with ARVD. The DRASTIC study
randomized to revascularization, all patients with renal
vascular lesions > 50% with diastolic blood pressure > 95
mmHg on only 2 medications. Thus patients with isolated
systolic hypertension or patients who would have
responded to 3 or more medications were excluded in that
study. Recruitment of patients for renal vascular disease
can be difficult as demonstrated by the ongoing CORAL
study with fewer than 25% enrolled more than 50% into
the planned enrollment period. Indeed, in the first six
months of enrollment fewer patients were seen in clinic
than expected (40 vs 80) and less than 10% of these had
indications for revascularization.
Discussion
The RAVE study seeks to determine if a subset of patients
with renovascular disease can be spared from invasive and
expensive testing and possibly fruitless invasive proce-
dures. If the renal resistance index can successfully iden-
tify those in whom microvascular disease has already
damaged the affected kidney to the point that renal revas-
cularization is not beneficial, it can serve a useful purpose
in the management of this condition. The failure of previ-
ous revascularization studies to demonstrate a benefit
may have been due to the inclusion of subjects with
microvascular disease that would not benefit from treat-
ment. This test if prospectively demonstrated to be of ben-
Table 5: Expected distribution of patients in study according to RRI status and need for revascularization assuming 240 patients 
screened
Total patients 240


















Table 4: Baseline and ongoing data collection
Baseline data:
• Blood pressure will be measured at each visit using the BpTru (VSM Technologies, Vancouver, Canada)
• serum creatinine.
• U/S abdomen for renal size and Doppler presence of renal artery stenosis
• Percent function of both kidneys and change with captopril on renal scan
• MR/CT angiography to determine presence or absence of renal artery stenosis
• Med review
• allergies
• Past surgery, hospitalizations
• Initial History and physical
• Labs, urine/blood
• ECG
Follow-up lab data: every 3 months
• Urea and creatinine
• Lipids q6 months
• U/S annually for renal sizeBMC Nephrology 2007, 8:4 http://www.biomedcentral.com/1471-2369/8/4
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efit may help to select a cohort of subjects that will benefit
from further assessment and renal revascularization.
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